David Evans, PhDCo-Founder and CSO at Sirnaomics
David M. Evans, Ph.D, Co-founder and CSO, Sirnaomics Inc. Gaithersburg, MD. Dr. Evans has over 25 years experience in drug target and small molecule discovery for oncology, infectious diseases and CNS therapeutics. He has been involved in the RNAi field since 2003. As Head of Drug Discovery for the Cancer Drug Development Lab for TGEN and as Sr. Director, RNAi Discovery and Therapeutic Services group, Dharmacon group, Thermo Fisher Scientific (TFS), he built HTS operations to identify targets that synergized with known oncology therapeutics. In 2008 Davidwas a cofounder of Sirnaomics and has led the R&D group with afocus on using siRNAs as therapeutics in their own right. Sirnaomics now has several candidates in clinical testing and a
rich pipeline of preclinical products. David received his BSc(1983) and PhD (1987) from Imperial College, London and has published a number of peer reviewed papers and review articles.